Review



nectin4 antibody  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Miltenyi Biotec nectin4 antibody
    Nectin4 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nectin4+antibody/Nectin-4+Antibody%2C+anti-human%2C+PE%2C+REAfinity/pm40931013-265-14-16
    Average 94 stars, based on 8 article reviews
    nectin4 antibody - by Bioz Stars, 2026-09
    94/100 stars

    Images

    Related Articles

    Staining:

    Article Title: Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer
    Article Snippet: 48–72 h after transfection, GFP-positive cells were sorted by FACS (BD Fusion) and expanded. .. Cells were then stained with a NECTIN4 antibody (Miltenyi, clone REA967, 1:100), sorted a second time by FACS (BD Fusion), and negative cells were collected and expanded. .. For generating NECTIN4 overexpressing cells, the NECTIN4 open reading frame (Horizon, clone ID 100006134) was cloned into lentiviral vectors pCMV-V5-Blast (a gift from Dr. Minkyu Kim) using Gateway cloning protocols (ThermoFisher).

    Article Title: Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer.
    Article Snippet: .. Overexpression was validated byWB and by surface protein staining and flow cytometry using the NECTIN4 antibody (Miltenyi, clone REA967, 1:100). .. Generation of enfortumab vedotin (EV) resistant cells RT112 cells were repeatedly exposed to EV (SeaGen) for 3-5 days, with dose escalation of 5 μg/ml per treatment cycle, for a total of 6 Nature Communications | (2025) 16:8215 11 treatment cycles.

    Article Title: Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer
    Article Snippet: .. Overexpression was validated by WB and by surface protein staining and flow cytometry using the NECTIN4 antibody (Miltenyi, clone REA967, 1:100). .. RT112 cells were repeatedly exposed to EV (SeaGen) for 3-5 days, with dose escalation of 5 μg/ml per treatment cycle, for a total of 6 treatment cycles.

    FACS:

    Article Title: Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer
    Article Snippet: 48–72 h after transfection, GFP-positive cells were sorted by FACS (BD Fusion) and expanded. .. Cells were then stained with a NECTIN4 antibody (Miltenyi, clone REA967, 1:100), sorted a second time by FACS (BD Fusion), and negative cells were collected and expanded. .. For generating NECTIN4 overexpressing cells, the NECTIN4 open reading frame (Horizon, clone ID 100006134) was cloned into lentiviral vectors pCMV-V5-Blast (a gift from Dr. Minkyu Kim) using Gateway cloning protocols (ThermoFisher).

    Over Expression:

    Article Title: Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer.
    Article Snippet: .. Overexpression was validated byWB and by surface protein staining and flow cytometry using the NECTIN4 antibody (Miltenyi, clone REA967, 1:100). .. Generation of enfortumab vedotin (EV) resistant cells RT112 cells were repeatedly exposed to EV (SeaGen) for 3-5 days, with dose escalation of 5 μg/ml per treatment cycle, for a total of 6 Nature Communications | (2025) 16:8215 11 treatment cycles.

    Article Title: Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer
    Article Snippet: .. Overexpression was validated by WB and by surface protein staining and flow cytometry using the NECTIN4 antibody (Miltenyi, clone REA967, 1:100). .. RT112 cells were repeatedly exposed to EV (SeaGen) for 3-5 days, with dose escalation of 5 μg/ml per treatment cycle, for a total of 6 treatment cycles.

    Flow Cytometry:

    Article Title: Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer.
    Article Snippet: .. Overexpression was validated byWB and by surface protein staining and flow cytometry using the NECTIN4 antibody (Miltenyi, clone REA967, 1:100). .. Generation of enfortumab vedotin (EV) resistant cells RT112 cells were repeatedly exposed to EV (SeaGen) for 3-5 days, with dose escalation of 5 μg/ml per treatment cycle, for a total of 6 Nature Communications | (2025) 16:8215 11 treatment cycles.

    Article Title: Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer
    Article Snippet: .. Overexpression was validated by WB and by surface protein staining and flow cytometry using the NECTIN4 antibody (Miltenyi, clone REA967, 1:100). .. RT112 cells were repeatedly exposed to EV (SeaGen) for 3-5 days, with dose escalation of 5 μg/ml per treatment cycle, for a total of 6 treatment cycles.

    Western Blot:

    Article Title: Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer
    Article Snippet: .. Overexpression was validated by WB and by surface protein staining and flow cytometry using the NECTIN4 antibody (Miltenyi, clone REA967, 1:100). .. RT112 cells were repeatedly exposed to EV (SeaGen) for 3-5 days, with dose escalation of 5 μg/ml per treatment cycle, for a total of 6 treatment cycles.



    Similar Products

    nectin4 antibody  (Miltenyi Biotec)
    94
    Miltenyi Biotec nectin4 antibody
    Nectin4 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nectin4+antibody/Nectin-4+Antibody%2C+anti-human%2C+PE%2C+REAfinity/pm40931013-265-14-16
    Average 94 stars, based on 1 article reviews
    nectin4 antibody - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    nectin4  (Proteintech)
    94
    Proteintech nectin4
    ITGB4 positively correlated with enfortumab vedotin target <t>NECTIN4.</t> A , the RNA-Seq analysis in the GSE268855 dataset after overexpressing ITGB4 ; B , the correlation analysis in the DepMap dataset. p values are shown in the figure. C , Pan-cancer data analysis in the DepMap database revealed the correlation between ITGB4 and NECTIN4 . p values were shown in the figure. D – G , HT-1376 and 5637 cells were transfected with shITGB4 or shControl for 72 h. The harvested cells were used for Western blot analysis ( D ) and RT-qPCR detection ( E – G ). H – K , HT-1376 and 5637 cells were transfected with overexpressed ITGB4 plasmid or empty vector for 72 h, and harvested cells were used for Western blot analysis ( H ) and RT-qPCR detection ( I–K ). Data presents as mean ± SD with three replicates. ns, not significant; ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001. L , the tissue microarray of bladder cancer stained with ITGB4 and NECTIN4, respectively. The typical IHC images stained with ITGB4 and NECTIN4 are shown in the panel . M , the correlation of these two proteins is shown in the panel , and the p -value is indicated in the figure.
    Nectin4, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nectin4+antibody/PVRL4+Antibody/pmc12753226-159-52-54
    Average 94 stars, based on 1 article reviews
    nectin4 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    anti nectin4 pe antibody  (Miltenyi Biotec)
    94
    Miltenyi Biotec anti nectin4 pe antibody
    ITGB4 positively correlated with enfortumab vedotin target <t>NECTIN4.</t> A , the RNA-Seq analysis in the GSE268855 dataset after overexpressing ITGB4 ; B , the correlation analysis in the DepMap dataset. p values are shown in the figure. C , Pan-cancer data analysis in the DepMap database revealed the correlation between ITGB4 and NECTIN4 . p values were shown in the figure. D – G , HT-1376 and 5637 cells were transfected with shITGB4 or shControl for 72 h. The harvested cells were used for Western blot analysis ( D ) and RT-qPCR detection ( E – G ). H – K , HT-1376 and 5637 cells were transfected with overexpressed ITGB4 plasmid or empty vector for 72 h, and harvested cells were used for Western blot analysis ( H ) and RT-qPCR detection ( I–K ). Data presents as mean ± SD with three replicates. ns, not significant; ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001. L , the tissue microarray of bladder cancer stained with ITGB4 and NECTIN4, respectively. The typical IHC images stained with ITGB4 and NECTIN4 are shown in the panel . M , the correlation of these two proteins is shown in the panel , and the p -value is indicated in the figure.
    Anti Nectin4 Pe Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nectin4+antibody/Nectin-4+Antibody%2C+anti-human%2C+PE%2C+REAfinity/pm40931013-296-16-23
    Average 94 stars, based on 1 article reviews
    anti nectin4 pe antibody - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    anti nectin4 viobright v423  (Miltenyi Biotec)
    94
    Miltenyi Biotec anti nectin4 viobright v423
    ITGB4 positively correlated with enfortumab vedotin target <t>NECTIN4.</t> A , the RNA-Seq analysis in the GSE268855 dataset after overexpressing ITGB4 ; B , the correlation analysis in the DepMap dataset. p values are shown in the figure. C , Pan-cancer data analysis in the DepMap database revealed the correlation between ITGB4 and NECTIN4 . p values were shown in the figure. D – G , HT-1376 and 5637 cells were transfected with shITGB4 or shControl for 72 h. The harvested cells were used for Western blot analysis ( D ) and RT-qPCR detection ( E – G ). H – K , HT-1376 and 5637 cells were transfected with overexpressed ITGB4 plasmid or empty vector for 72 h, and harvested cells were used for Western blot analysis ( H ) and RT-qPCR detection ( I–K ). Data presents as mean ± SD with three replicates. ns, not significant; ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001. L , the tissue microarray of bladder cancer stained with ITGB4 and NECTIN4, respectively. The typical IHC images stained with ITGB4 and NECTIN4 are shown in the panel . M , the correlation of these two proteins is shown in the panel , and the p -value is indicated in the figure.
    Anti Nectin4 Viobright V423, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nectin4+antibody/Nectin-4+Antibody%2C+anti-human%2C+Vio+Bright+V423%2C+REAfinity/pm40931013-296-20-23
    Average 94 stars, based on 1 article reviews
    anti nectin4 viobright v423 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    ITGB4 positively correlated with enfortumab vedotin target NECTIN4. A , the RNA-Seq analysis in the GSE268855 dataset after overexpressing ITGB4 ; B , the correlation analysis in the DepMap dataset. p values are shown in the figure. C , Pan-cancer data analysis in the DepMap database revealed the correlation between ITGB4 and NECTIN4 . p values were shown in the figure. D – G , HT-1376 and 5637 cells were transfected with shITGB4 or shControl for 72 h. The harvested cells were used for Western blot analysis ( D ) and RT-qPCR detection ( E – G ). H – K , HT-1376 and 5637 cells were transfected with overexpressed ITGB4 plasmid or empty vector for 72 h, and harvested cells were used for Western blot analysis ( H ) and RT-qPCR detection ( I–K ). Data presents as mean ± SD with three replicates. ns, not significant; ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001. L , the tissue microarray of bladder cancer stained with ITGB4 and NECTIN4, respectively. The typical IHC images stained with ITGB4 and NECTIN4 are shown in the panel . M , the correlation of these two proteins is shown in the panel , and the p -value is indicated in the figure.

    Journal: The Journal of Biological Chemistry

    Article Title: Integrin β4 drives immune evasion and therapeutic resistance to PD-1 blockade in bladder cancer via MEK/ERK signaling

    doi: 10.1016/j.jbc.2025.110941

    Figure Lengend Snippet: ITGB4 positively correlated with enfortumab vedotin target NECTIN4. A , the RNA-Seq analysis in the GSE268855 dataset after overexpressing ITGB4 ; B , the correlation analysis in the DepMap dataset. p values are shown in the figure. C , Pan-cancer data analysis in the DepMap database revealed the correlation between ITGB4 and NECTIN4 . p values were shown in the figure. D – G , HT-1376 and 5637 cells were transfected with shITGB4 or shControl for 72 h. The harvested cells were used for Western blot analysis ( D ) and RT-qPCR detection ( E – G ). H – K , HT-1376 and 5637 cells were transfected with overexpressed ITGB4 plasmid or empty vector for 72 h, and harvested cells were used for Western blot analysis ( H ) and RT-qPCR detection ( I–K ). Data presents as mean ± SD with three replicates. ns, not significant; ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001. L , the tissue microarray of bladder cancer stained with ITGB4 and NECTIN4, respectively. The typical IHC images stained with ITGB4 and NECTIN4 are shown in the panel . M , the correlation of these two proteins is shown in the panel , and the p -value is indicated in the figure.

    Article Snippet: The primary antibodies used were as follows: ITGB4 (#21738-1-AP, Proteintech, 1:500 dilution), p-ITGB4(Y1510) (#YP0755, Immunoway, 1:500 dilution), MEK-1(#YM8273, Immunoway, 1:1000 dilution), p-MEK-1 (T386) (#YP0425, Immunoway, 1:500 dilution), ERK1/2(#YM8336, Immunoway, 1:2000 dilution), p-ERK1/2 (T202/T204) (#YM8452, Immunoway, 1:2000 dilution), c-Jun (#YM8321, Immunoway, 1:2000 dilution), p-c-Jun (S63) (#28907-1-AP, Proteintech, 1:500 dilution), PD-L1(#28076-1-AP, Proteintech, 1:300 dilution), NECTIN4 (#21903-1-AP, Proteintech, 1:2000 dilution), HER2(#18299-1-AP, Proteintech, 1:2000 dilution), TROP2(#27360-1-AP, Proteintech, 1:500 dilution), GADPH (#10494-1-AP, Proteintech, 1:5000 dilution).

    Techniques: RNA Sequencing, Transfection, Western Blot, Quantitative RT-PCR, Plasmid Preparation, Microarray, Staining

    ITGB4 plays a vital role in BLCA sequential therapies. A mechanism diagram depicting that the highly expressed ITGB4 in cisplatin-resistant BLCA activated the MEK/ERK pathway through tyrosine-1510 phosphorylation, upregulated the expression level of PD-L1 in BLCA, and caused anti-PD-1 treatment resistance. Meanwhile, the overexpressed ITGB4 was positively correlated to NECTIN4, promoting the sensitivity of BLCA to enfortumab vedotin treatment.

    Journal: The Journal of Biological Chemistry

    Article Title: Integrin β4 drives immune evasion and therapeutic resistance to PD-1 blockade in bladder cancer via MEK/ERK signaling

    doi: 10.1016/j.jbc.2025.110941

    Figure Lengend Snippet: ITGB4 plays a vital role in BLCA sequential therapies. A mechanism diagram depicting that the highly expressed ITGB4 in cisplatin-resistant BLCA activated the MEK/ERK pathway through tyrosine-1510 phosphorylation, upregulated the expression level of PD-L1 in BLCA, and caused anti-PD-1 treatment resistance. Meanwhile, the overexpressed ITGB4 was positively correlated to NECTIN4, promoting the sensitivity of BLCA to enfortumab vedotin treatment.

    Article Snippet: The primary antibodies used were as follows: ITGB4 (#21738-1-AP, Proteintech, 1:500 dilution), p-ITGB4(Y1510) (#YP0755, Immunoway, 1:500 dilution), MEK-1(#YM8273, Immunoway, 1:1000 dilution), p-MEK-1 (T386) (#YP0425, Immunoway, 1:500 dilution), ERK1/2(#YM8336, Immunoway, 1:2000 dilution), p-ERK1/2 (T202/T204) (#YM8452, Immunoway, 1:2000 dilution), c-Jun (#YM8321, Immunoway, 1:2000 dilution), p-c-Jun (S63) (#28907-1-AP, Proteintech, 1:500 dilution), PD-L1(#28076-1-AP, Proteintech, 1:300 dilution), NECTIN4 (#21903-1-AP, Proteintech, 1:2000 dilution), HER2(#18299-1-AP, Proteintech, 1:2000 dilution), TROP2(#27360-1-AP, Proteintech, 1:500 dilution), GADPH (#10494-1-AP, Proteintech, 1:5000 dilution).

    Techniques: Phospho-proteomics, Expressing